Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Olivier Benichou
Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (cDMARDs) in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors
RMD Open
Rheumatology
Allergy
Immunology
Related publications
Efficacy and Safety of Baricitinib for Active Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic or Biological Disease‑modifying Anti‑rheumatic Drugs: A Meta‑analysis of Randomized Controlled Trials
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond
RMD Open
Rheumatology
Allergy
Immunology
Comparison of the Efficacy of the Tumour Necrosis Factor Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients With Active Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Assessing the Effectiveness of Synthetic and Biologic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis &Ndash; A Systematic Review
Psoriasis: Targets and Therapy
Dermatology
Rheumatology
Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs
Reumatologia
Rheumatology
Allergy
Immunology
Comparative Effectiveness of Tocilizumab Versus TNF Inhibitors as Monotherapy or in Combination With Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis After the Use of at Least One Biologic Disease-Modifying Antirheumatic Drug: Analyses From the Pan-European TOCERRA Register Collaboration
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Cost-Effectiveness of Combination Disease-Modifying Antirheumatics vs. Tumour Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: TACIT Trial
Arthritis Care and Research
Rheumatology
Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study
Arthritis Research & Therapy
Association Between Use of Disease-Modifying Antirheumatic Drugs and Diabetes in Patients With Ankylosing Spondylitis, Rheumatoid Arthritis, or Psoriasis/Psoriatic Arthritis: A Nationwide, Population-Based Cohort Study of 84,989 Patients
Therapeutics and Clinical Risk Management
